– Data from the CheckMate 040 trial presented at the 2020 American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium – January 24, 2020 07:30 AM Eastern Standard Time ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (NASDAQ: EXEL) today...
HANGZHOU and SHAOXING, China, Jan. 22, 2020 /PRNewswire/ — Ascletis Pharma Inc. (Ascletis, 1672.HK) announces today the approval for ASC22 to conduct clinical trials in chronic hepatitis B patients in China from China’s National Medical Products...
Study meets primary endpoint in patients living with type 1 SMA To date, more than 400 patients have been treated with risdiplam across all studies, with no treatment related safety findings leading to study withdrawal in any risdiplam trial Risdiplam PDUFA expected...
BOULDER, Colo., Jan. 23, 2020 (GLOBE NEWSWIRE) — miRagen Therapeutics Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company developing proprietary RNA-targeted therapies with a specific focus on microRNAs, today announced that it will present new...
PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that both batches of the company’s manufactured...
Email
Text